Oncternal Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2020
Period Ending	Apr '25 Apr 30, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2020
Net Income	-4.41	-3.63	-7.48	-12.75	-2.73	-1.96	Upgrade
Loss (Gain) From Sale of Investments	1.74	2.52	5.88	9.28	-0.76	-1.46	Upgrade
Stock-Based Compensation	1.77	-	0.06	1.99	0.51	1.77	Upgrade
Provision & Write-off of Bad Debts	-	-	0.05	-	-	-	Upgrade
Other Operating Activities	0.01	0.3	0.38	-0.16	0.14	-0.01	Upgrade
Change in Accounts Receivable	-0	-	0.03	-0.13	-	-	Upgrade
Change in Accounts Payable	0.32	0.38	0.36	0.66	0.34	0.09	Upgrade
Change in Other Net Operating Assets	0.13	0.32	0.13	-0.28	-0.44	-0.66	Upgrade
Operating Cash Flow	-0.45	-0.11	-0.59	-1.39	-2.94	-2.23	Upgrade
Issuance of Common Stock	0.92	0.04	0.56	-	2.79	3.36	Upgrade
Other Financing Activities	-0	-0	-0.01	-	-0.01	-0.17	Upgrade
Financing Cash Flow	0.97	0.03	0.55	-	2.78	3.19	Upgrade
Net Cash Flow	0.52	-0.08	-0.04	-1.39	-0.16	0.96	Upgrade
Levered Free Cash Flow	-0.82	-1.46	-3.37	-	0.48	-	Upgrade
Unlevered Free Cash Flow	-0.81	-1.46	-3.37	-	0.48	-	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.